Meeder Asset Management’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-4,159
| Closed | -$13K | – | 2478 |
|
|
2022
Q2 | $13K | Sell |
4,159
-153
| -4% | -$596 | ﹤0.01% | 1299 |
|
|
2022
Q1 | $18K | Buy |
+4,312
| New | +$18.8K | ﹤0.01% | 1342 |
|
|
2021
Q4 | – | Sell |
-4,282
| Closed | -$17K | – | 2629 |
|
|
2021
Q3 | $17K | Hold |
4,282
| – | – | ﹤0.01% | 1487 |
|
|
2021
Q2 | $18K | Buy |
4,282
+2,037
| +91% | +$8.73K | ﹤0.01% | 1503 |
|
|
2021
Q1 | $8K | Buy |
+2,245
| New | +$12.4K | ﹤0.01% | 1716 |
|
|
2020
Q2 | – | Sell |
-804
| Closed | -$3K | – | 2734 |
|
|
2020
Q1 | $3K | Buy |
804
+789
| +5,260% | +$4.98K | ﹤0.01% | 2044 |
|
|
2019
Q4 | $0 | Buy |
+15
| New | +$89 | ﹤0.01% | 2571 |
|
|
2019
Q3 | – | Sell |
-318
| Closed | -$3K | – | 2378 |
|
|
2019
Q2 | $3K | Buy |
+318
| New | +$2.4K | ﹤0.01% | 1838 |
|
|
2019
Q1 | – | Sell |
-106
| Closed | -$1K | – | 2009 |
|
|
2018
Q4 | $1K | Buy |
+106
| New | +$1.59K | ﹤0.01% | 1694 |
|
|
2017
Q2 | – | Sell |
-159
| Closed | -$5K | – | 2109 |
|
|
2017
Q1 | $5K | Sell |
159
-613
| -79% | -$15.7K | ﹤0.01% | 1138 |
|
|
2016
Q4 | $14K | Buy |
+772
| New | +$14.8K | ﹤0.01% | 706 |
|
Meeder Asset Management's LJPC Position: Q3 2022 in Review
Meeder Asset Management sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 4,159 shares — an estimated $13K sold.
Meeder Asset Management first reported a position in LJPC in Q4 2016 and held it in 11 quarters. The position peaked at $18K in Q1 2022. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- Meeder Asset Management reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- Meeder Asset Management sold 4,159 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $13K.
- Meeder Asset Management first reported a position in La Jolla Pharmaceutical Company in Q4 2016 and held it in 11 quarters.
- Meeder Asset Management's La Jolla Pharmaceutical Company position peaked at $18K in Q1 2022.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on Meeder Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.